{
  "id": 17990464,
  "title": "Ionis earnings on deck: Can Tryngolza justify blockbuster hype?",
  "url": "https://urgent.news/2026/11/03/ionis-earnings-on-deck-can-tryngolza-justify-blockbuster-hype",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-03T16:52:03.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/ionis-earnings-on-deck-can-tryngolza-justify-blockbuster-hype-93CH-4996044"
  },
  "original_language": "en",
  "account": "Ionis Pharmaceuticals is set to unveil its third-quarter earnings on November 4, with investors keen to determine whether the company's high-stakes bet on Tryngolza can turn around its recent stock slump. Analysts forecast a loss of $1.21 per share and revenue of $183.12 million, showing a significant decline from the previous quarter, when Ionis reported a $0.69 loss per share on $268 million in revenue. The projected loss is 51% higher than the second quarter and 2% lower than the EPS estimates from last quarter, while revenue estimates remain stable. Tryngolza, FDA-approved in June 2026 to lower triglycerides and pancreatitis risk in severe hypertriglyceridemia patients, has shown early launch momentum despite the stock's 46% decline this year. Analyst sentiment remains overwhelmingly bullish, with 21 out of 25 analysts rating shares as Buy and a mean price target of $84.13, indicating a 104% upside potential. The approval marks Ionis's first independent commercial rollout in a prevalent disease, signaling a shift from focusing on rare conditions. Investors will closely monitor prescription trends, payer coverage, and the company's confidence in achieving its $100 million to $110 million sales guidance for Tryngolza in 2026. GSK's Hibsago hepatitis B treatment, partnered with Ionis, received FDA approval on October 20, providing a new royalty stream of 10% to 12% on sales. Roche's sefaxersen, showing positive Phase 3 data for IgA nephropathy, could also generate a high-teen to 20% royalty for Ionis. The upcoming earnings report will reveal if Ionis can maintain execution momentum and justify the premium valuation for Tryngolza's commercial success.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}